{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:39:59Z","timestamp":1784241599768,"version":"3.55.0"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.mce.2024.112295","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T05:17:16Z","timestamp":1718169436000},"page":"112295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Fundamentals and recent advances in the evaluation and management of medullary thyroid carcinoma"],"prefix":"10.1016","volume":"592","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6733-7132","authenticated-orcid":false,"given":"Benjamin J.","family":"Gigliotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-3405","authenticated-orcid":false,"given":"Jennifer A.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2629-2289","authenticated-orcid":false,"given":"Lori J.","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.mce.2024.112295_bib1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ijsu.2017.02.064","article-title":"Genetics of medullary thyroid cancer: an overview","volume":"41","author":"Accardo","year":"2017","journal-title":"Int. J. Surg."},{"issue":"2","key":"10.1016\/j.mce.2024.112295_bib2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/SLA.0000000000001688","article-title":"Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes?","volume":"265","author":"Adam","year":"2017","journal-title":"Ann. Surg."},{"issue":"9","key":"10.1016\/j.mce.2024.112295_bib3","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/jamasurg.2017.1665","article-title":"Rethinking the current American joint committee on cancer TNM staging system for medullary thyroid cancer","volume":"152","author":"Adam","year":"2017","journal-title":"JAMA Surg."},{"issue":"3","key":"10.1016\/j.mce.2024.112295_bib4","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/ajcp\/aqab141","article-title":"Performing calcitonin immunocytochemistry on an additional ThinPrep slide in fine-needle aspiration diagnosis of medullary thyroid carcinoma","volume":"157","author":"Ahmed","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.mce.2024.112295_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104878","article-title":"Cost-effectiveness of routine calcitonin screening and fine-needle aspiration biopsy in preoperative diagnosis of medullary thyroid Cancer in the United States","volume":"110","author":"Al-Qurayshi","year":"2020","journal-title":"Oral Oncol."},{"issue":"6","key":"10.1016\/j.mce.2024.112295_bib6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: management guidelines of the American Thyroid Association","volume":"19","author":"Kloos","year":"2009","journal-title":"Thyroid"},{"issue":"7","key":"10.1016\/j.mce.2024.112295_bib7","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1530\/ERC-21-0368","article-title":"Metastatic medullary thyroid carcinoma: a new way forward","volume":"29","author":"Angelousi","year":"2022","journal-title":"Endocr. Relat. Cancer"},{"issue":"11","key":"10.1016\/j.mce.2024.112295_bib8","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1210\/jc.2005-0044","article-title":"Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma","volume":"90","author":"Barbet","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2024.112295_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/lary.30633","article-title":"Identifying parathyroids in pediatric thyroid\/parathyroid surgery by near infrared autofluorescence","author":"Belcher","year":"2023","journal-title":"Laryngoscope"},{"key":"10.1016\/j.mce.2024.112295_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.omto.2021.01.012","article-title":"Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4","volume":"20","author":"Bhoj","year":"2021","journal-title":"Mol Ther Oncolytics"},{"issue":"10","key":"10.1016\/j.mce.2024.112295_bib11","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.2967\/jnumed.116.172221","article-title":"Immuno-PET using anticarcinoembryonic antigen bispecific antibody and 68Ga-labeled peptide in metastatic medullary thyroid carcinoma: clinical optimization of the pretargeting parameters in a first-in-human trial","volume":"57","author":"Bodet-Milin","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.mce.2024.112295_bib12","article-title":"Selpercatinib-induced hypothyroidism through off-target inhibition of type 2 iodothyronine deiodinase","volume":"6","author":"Boucai","year":"2022","journal-title":"JCO Precis Oncol."},{"issue":"3","key":"10.1016\/j.mce.2024.112295_bib13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.eprac.2022.10.179","article-title":"A decade of progress in targeted therapy for advanced thyroid cancer: an overview","volume":"29","author":"Cabanillas","year":"2023","journal-title":"Endocr. Pract."},{"issue":"9","key":"10.1016\/j.mce.2024.112295_bib14","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1210\/jc.2018-00193","article-title":"Comparison of 68Ga PET\/CT to other imaging studies in medullary thyroid cancer: superiority in detecting bone metastases","volume":"103","author":"Castroneves","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.mce.2024.112295_bib15","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1309\/AJCPHWACTTUYJ7DD","article-title":"Molecular pathology of hereditary and sporadic medullary thyroid carcinomas","volume":"143","author":"Chernock","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.mce.2024.112295_bib16","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1210\/jc.2007-2496","article-title":"Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis","volume":"93","author":"Cheung","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2024.112295_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107708","article-title":"Role of tissue and circulating microRNAs and DNA as biomarkers in medullary thyroid cancer","volume":"219","author":"Chiacchiarini","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.mce.2024.112295_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009686","article-title":"Dynamic risk stratification in medullary thyroid carcinoma: single institution experiences","volume":"97","author":"Choi","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.mce.2024.112295_bib19","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/thy.2022.0506","article-title":"Neoadjuvant selective RET inhibitor for medullary thyroid cancer: a case series","volume":"33","author":"Contrera","year":"2023","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.mce.2024.112295_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1439","article-title":"Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US","volume":"6","author":"Cooperberg","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.mce.2024.112295_bib22","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa527","article-title":"CD133 expression in medullary thyroid cancer cells identifies patients with poor prognosis","author":"Cordero-Barreal","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.mce.2024.112295_bib23","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1089\/thy.2010.0297","article-title":"Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada","volume":"21","author":"Daniels","year":"2011","journal-title":"Thyroid"},{"key":"10.1016\/j.mce.2024.112295_bib24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3389\/fendo.2020.00490","article-title":"A case report of sequential use of a yeast-CEA therapeutic cancer vaccine and anti-PD-L1 inhibitor in metastatic medullary thyroid cancer","volume":"11","author":"Del Rivero","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.mce.2024.112295_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.mce.2024.112295_bib26","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent- front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.mce.2024.112295_bib27","article-title":"Treatment of medullary thyroid cancer with bone metastases with denosumab: a review and case illustration","volume":"17","author":"Eldeiry","year":"2020","journal-title":"J. Clin. Transl. Endocrinol.: Case Reports"},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1210\/jc.2003-030550","article-title":"Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders","volume":"89","author":"Elisei","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.mce.2024.112295_bib29","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.1210\/jc.2007-1005","article-title":"RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center","volume":"92","author":"Elisei","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"29","key":"10.1016\/j.mce.2024.112295_bib30","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J. Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.mce.2024.112295_bib31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1530\/EJE-15-0304","article-title":"Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer","volume":"173","author":"Elisei","year":"2015","journal-title":"Eur. J. Endocrinol."},{"issue":"9","key":"10.1016\/j.mce.2024.112295_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/genes10090698","article-title":"Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations","volume":"10","author":"Elisei","year":"2019","journal-title":"Genes"},{"issue":"9","key":"10.1016\/j.mce.2024.112295_bib33","first-page":"2167","article-title":"Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma","volume":"56","author":"Eng","year":"1996","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.mce.2024.112295_bib34","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and clinical perspectives on thyroid cancer","volume":"375","author":"Fagin","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.mce.2024.112295_bib35","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.mce.2024.112295_bib36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/archinte.168.6.587","article-title":"Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample","volume":"168","author":"Fox","year":"2008","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.mce.2024.112295_bib37","doi-asserted-by":"crossref","first-page":"R197","DOI":"10.1530\/EJE-20-0506","article-title":"Endocrine tumours: calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus","volume":"183","author":"Giannetta","year":"2020","journal-title":"Eur. J. Endocrinol."},{"issue":"6","key":"10.1016\/j.mce.2024.112295_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/eci.12934","article-title":"Procalcitonin measurement to screen medullary thyroid carcinoma: a prospective evaluation in a series of 2705 patients with thyroid nodules","volume":"48","author":"Giovanella","year":"2018","journal-title":"Eur. J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00259-019-04458-6","article-title":"EANM practice guideline for PET\/CT imaging in medullary thyroid carcinoma","volume":"47","author":"Giovanella","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"12","key":"10.1016\/j.mce.2024.112295_bib40","first-page":"3634","article-title":"Procalcitonin as an alternative tumor marker of medullary thyroid carcinoma","volume":"106","author":"Giovanella","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.mce.2024.112295_bib41","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1089\/thy.2016.0224","article-title":"Role of CDKN2C copy number in sporadic medullary thyroid carcinoma","volume":"26","author":"Grubbs","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.mce.2024.112295_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.896287","article-title":"Peptide receptor radionuclide therapy in thyroid cancer","volume":"13","author":"Gubbi","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.mce.2024.112295_bib43","author":"Haddad"},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines Task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2015","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib45","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/jcem-19-1-152","article-title":"Medullary (solid) carcinoma of the thyroid\u2014a clinicopathologic entity","volume":"19","author":"HAZARD","year":"1959","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"6","key":"10.1016\/j.mce.2024.112295_bib46","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000445978","article-title":"Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma","volume":"90","author":"Heilmann","year":"2016","journal-title":"Oncology"},{"issue":"11","key":"10.1016\/j.mce.2024.112295_bib47","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1089\/thy.2019.0041","article-title":"A novel ALK fusion in pediatric medullary thyroid carcinoma","volume":"29","author":"Hillier","year":"2019","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.mce.2024.112295_bib48","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1245\/s10434-014-4208-2","article-title":"Postoperative nomogram for predicting cancer-specific mortality in medullary thyroid cancer","volume":"22","author":"Ho","year":"2015","journal-title":"Ann. Surg Oncol."},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib49","article-title":"A systematic review of neoadjuvant targeted therapy in locally advanced thyroid cancer","volume":"1","author":"Huang","year":"2022","journal-title":"Holistic Integr. Oncol."},{"issue":"2","key":"10.1016\/j.mce.2024.112295_bib50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5306\/wjco.v14.i2.40","article-title":"Hereditary cancer syndromes","volume":"14","author":"Imyanitov","year":"2023","journal-title":"World J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.mce.2024.112295_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113268","article-title":"Results and clinical interpretation of germline RET analysis in a series of patients with medullary thyroid carcinoma: the challenge of the variants of uncertain significance","volume":"12","author":"Innella","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.mce.2024.112295_bib52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.21037\/aot-2020-rcmtt-06","article-title":"Active surveillance for low-risk papillary thyroid microcarcinomas","volume":"5","author":"Ito","year":"2020","journal-title":"Annals of Thyroid"},{"issue":"7","key":"10.1016\/j.mce.2024.112295_bib53","doi-asserted-by":"crossref","DOI":"10.1177\/03000605221110698","article-title":"Management of medullary carcinoma of the thyroid: a review","volume":"50","author":"Jayasinghe","year":"2022","journal-title":"J. Int. Med. Res."},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0194599820947696","article-title":"External beam radiotherapy for medullary thyroid cancer following total or near-total thyroidectomy","volume":"164","author":"Jin","year":"2021","journal-title":"Otolaryngol. Head Neck Surg."},{"issue":"2","key":"10.1016\/j.mce.2024.112295_bib55","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a000729","article-title":"Putative BRAF activating fusion in a medullary thyroid cancer","volume":"2","author":"Kasaian","year":"2016","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"10.1016\/j.mce.2024.112295_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z","article-title":"Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems","volume":"88","author":"Kebebew","year":"2000","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.mce.2024.112295_bib57","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/archsurg.135.8.895","article-title":"Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer","volume":"135","author":"Kebebew","year":"2000","journal-title":"Arch. Surg."},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib58","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1245\/s10434-021-10980-5","article-title":"Outcomes of advanced medullary thyroid carcinoma in the era of targeted therapy","volume":"29","author":"Kesby","year":"2022","journal-title":"Ann. Surg Oncol."},{"issue":"7","key":"10.1016\/j.mce.2024.112295_bib59","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1158\/1055-9965.EPI-21-1440","article-title":"Epidemiology of thyroid cancer","volume":"31","author":"Kitahara","year":"2022","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"7","key":"10.1016\/j.mce.2024.112295_bib60","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.2967\/jnumed.118.221283","article-title":"DOTA-MGS5, a new cholecystokinin-2 receptor-targeting peptide analog with an optimized targeting profile for theranostic use","volume":"60","author":"Klingler","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.mce.2024.112295_bib61","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/thy.2020.0206","article-title":"Real-world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer","volume":"31","author":"Koehler","year":"2021","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.mce.2024.112295_bib62","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/cen.14617","article-title":"Medullary thyroid cancer with ectopic Cushing's syndrome: a multicentre case series","volume":"96","author":"Koehler","year":"2022","journal-title":"Clin. Endocrinol."},{"issue":"2","key":"10.1016\/j.mce.2024.112295_bib63","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s13304-017-0443-y","article-title":"Surgical management of medullary thyroid carcinoma","volume":"69","author":"Konstantinidis","year":"2017","journal-title":"Updates Surg."},{"issue":"24","key":"10.1016\/j.mce.2024.112295_bib64","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.19.02790","article-title":"Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA trial","volume":"38","author":"Kreissl","year":"2020","journal-title":"J. Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib65","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12902-021-00832-4","article-title":"Stereotactic radiotherapy is a useful treatment option for patients with medullary thyroid cancer","volume":"21","author":"Kukulska","year":"2021","journal-title":"BMC Endocr. Disord."},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib66","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamasurg.2017.3555","article-title":"Risk factors associated with reoperation and disease-specific mortality in patients with medullary thyroid carcinoma","volume":"153","author":"Kuo","year":"2018","journal-title":"JAMA Surg."},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib67","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s12020-015-0849-6","article-title":"Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy","volume":"53","author":"Kwon","year":"2016","journal-title":"Endocrine"},{"issue":"12","key":"10.1016\/j.mce.2024.112295_bib68","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.annonc.2020.09.015","article-title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","volume":"31","author":"Lin","year":"2020","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.mce.2024.112295_bib69","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1089\/thy.2014.0277","article-title":"Response to initial therapy predicts clinical outcomes in medullary thyroid cancer","volume":"25","author":"Lindsey","year":"2015","journal-title":"Thyroid"},{"issue":"16","key":"10.1016\/j.mce.2024.112295_bib70","doi-asserted-by":"crossref","first-page":"27520","DOI":"10.18632\/oncotarget.15897","article-title":"Ultrasonographic characteristics of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.mce.2024.112295_bib71","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1210\/jc.2009-2368","article-title":"Biomarker-based risk stratification for previously untreated medullary thyroid cancer","volume":"95","author":"Machens","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.mce.2024.112295_bib72","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archsurg.142.3.289","article-title":"Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis","volume":"142","author":"Machens","year":"2007","journal-title":"Arch. Surg."},{"issue":"5","key":"10.1016\/j.mce.2024.112295_bib73","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2265.2011.04293.x","article-title":"Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer","volume":"76","author":"Machens","year":"2012","journal-title":"Clin. Endocrinol."},{"issue":"8","key":"10.1016\/j.mce.2024.112295_bib74","doi-asserted-by":"crossref","first-page":"e2968","DOI":"10.1210\/clinem\/dgab214","article-title":"Exceptionality of distant metastasis in node-negative hereditary and sporadic medullary thyroid cancer: lessons learned","volume":"106","author":"Machens","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib75","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12885-021-08257-x","article-title":"Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review","volume":"21","author":"Maghsoomi","year":"2021","journal-title":"BMC Cancer"},{"issue":"16_Suppl. l","key":"10.1016\/j.mce.2024.112295_bib76","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1200\/JCO.2022.40.16_suppl.6080","article-title":"Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): updated data from the ARROW trial","volume":"40","author":"Mansfield","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.mce.2024.112295_bib77","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1089\/thy.2018.0564","article-title":"Survival and long-term biochemical cure in medullary thyroid carcinoma in Denmark 1997-2014: a nationwide study","volume":"29","author":"Mathiesen","year":"2019","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EC-18-0494","article-title":"Replication of newly proposed TNM staging system for medullary thyroid carcinoma: a nationwide study","volume":"8","author":"Mathiesen","year":"2019","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010094","article-title":"Impact of advanced age on the clinical presentation and outcome of sporadic medullary thyroid carcinoma","volume":"13","author":"Matrone","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.mce.2024.112295_bib80","doi-asserted-by":"crossref","DOI":"10.20517\/2394-4722.2021.47","article-title":"Systemic treatment of advanced, metastatic, medullary thyroid carcinoma","author":"Matrone","year":"2021","journal-title":"J. Cancer Metastasis and Treatment"},{"issue":"3","key":"10.1016\/j.mce.2024.112295_bib81","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000516469","article-title":"European thyroid association and cardiovascular and interventional radiological society of Europe 2021 clinical practice guideline for the use of minimally invasive treatments in malignant thyroid lesions","volume":"10","author":"Mauri","year":"2021","journal-title":"Eur. Thyroid J."},{"issue":"7","key":"10.1016\/j.mce.2024.112295_bib82","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/thy.2013.0045","article-title":"The increasing incidence of thyroid cancer: the influence of access to care","volume":"23","author":"Morris","year":"2013","journal-title":"Thyroid"},{"issue":"5","key":"10.1016\/j.mce.2024.112295_bib83","doi-asserted-by":"crossref","first-page":"R235","DOI":"10.1530\/ERC-15-0070","article-title":"RAS proto-oncogene in medullary thyroid carcinoma","volume":"22","author":"Moura","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib84","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41467-018-02994-7","article-title":"A secondary RET mutation in the activation loop conferring resistance to vandetanib","volume":"9","author":"Nakaoku","year":"2018","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.mce.2024.112295_bib85","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s12029-021-00646-6","article-title":"Interventional radiology approaches for liver metastases from thyroid cancer: a case series and overview of the literature","volume":"52","author":"Nervo","year":"2021","journal-title":"J. Gastrointest. Cancer"},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib86","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1385\/EP:13:1:03","article-title":"RET\/PTC rearrangement in thyroid tumors","volume":"13","author":"Nikiforov","year":"2002","journal-title":"Endocr. Pathol. Spring"},{"issue":"12","key":"10.1016\/j.mce.2024.112295_bib87","doi-asserted-by":"crossref","first-page":"R251","DOI":"10.1530\/EC-20-0374","article-title":"Current status of the prognostic molecular markers in medullary thyroid carcinoma","volume":"9","author":"Oczko-Wojciechowska","year":"2020","journal-title":"Endocr Connect"},{"issue":"3","key":"10.1016\/j.mce.2024.112295_bib88","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000499018","article-title":"The role of calcitonin in predicting the extent of surgery in medullary thyroid carcinoma: a nationwide population-based study in Norway","volume":"8","author":"Opsahl","year":"2019","journal-title":"Eur. Thyroid J."},{"issue":"2","key":"10.1016\/j.mce.2024.112295_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvir.2022.100825","article-title":"The treatment of thyroid cancer with radiofrequency ablation","volume":"25","author":"Pace-Asciak","year":"2022","journal-title":"Tech. Vasc. Intervent. Radiol."},{"issue":"6","key":"10.1016\/j.mce.2024.112295_bib90","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.clon.2010.05.002","article-title":"Medullary thyroid carcinoma","volume":"22","author":"Pacini","year":"2010","journal-title":"Clin. Oncol."},{"issue":"4","key":"10.1016\/j.mce.2024.112295_bib91","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1089\/thy.2016.0334","article-title":"Long-term control of hypercortisolism by vandetanib in a case of medullary thyroid carcinoma with a somatic RET mutation","volume":"27","author":"Paepegaey","year":"2017","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.mce.2024.112295_bib92","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/j.pbj.0000000000000018","article-title":"Diarrhea as a form of presentation of medullary thyroid carcinoma","volume":"3","author":"Pais","year":"2018","journal-title":"Porto Biomed. J."},{"issue":"3","key":"10.1016\/j.mce.2024.112295_bib93","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/hed.26024","article-title":"Clinical utility of (177) Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity","volume":"42","author":"Parghane","year":"2020","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib94","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41698-023-00347-2","article-title":"Genomic landscape of 891 RET fusions detected across diverse solid tumor types","volume":"7","author":"Parimi","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.mce.2024.112295_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.749973","article-title":"Prognostic value of preoperative serum calcitonin levels for predicting the recurrence of medullary thyroid carcinoma","volume":"12","author":"Park","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"9","key":"10.1016\/j.mce.2024.112295_bib96","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamasurg.2018.1153","article-title":"Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules","volume":"153","author":"Patel","year":"2018","journal-title":"JAMA Surg."},{"issue":"10","key":"10.1016\/j.mce.2024.112295_bib97","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1245\/s10434-009-0595-1","article-title":"Micromedullary thyroid cancer: how micro is truly micro?","volume":"16","author":"Pillarisetty","year":"2009","journal-title":"Ann. Surg Oncol."},{"issue":"10","key":"10.1016\/j.mce.2024.112295_bib98","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/bjs.10856","article-title":"Prophylactic thyroidectomy in children with multiple endocrine neoplasia type 2","volume":"105","author":"Prete","year":"2018","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.mce.2024.112295_bib99","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad061","article-title":"Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment","author":"Prete","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.mce.2024.112295_bib100","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0130","article-title":"Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer","volume":"11","author":"Puleo","year":"2022","journal-title":"Eur. Thyroid J."},{"issue":"5","key":"10.1016\/j.mce.2024.112295_bib101","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.3390\/curroncol29050282","article-title":"Successful treatment with selpercatinib for ectopic cushing's syndrome due to medullary thyroid cancer","volume":"29","author":"Ragnarsson","year":"2022","journal-title":"Curr. Oncol."},{"issue":"2","key":"10.1016\/j.mce.2024.112295_bib102","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12020-020-02426-x","article-title":"Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer","volume":"71","author":"Ramos","year":"2021","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib103","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.surg.2016.04.053","article-title":"Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years","volume":"161","author":"Randle","year":"2017","journal-title":"Surgery"},{"issue":"9","key":"10.1016\/j.mce.2024.112295_bib104","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1089\/thy.2022.0189","article-title":"Preoperative identification of medullary thyroid carcinoma (MTC): clinical validation of the afirma MTC RNA-sequencing classifier","volume":"32","author":"Randolph","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.mce.2024.112295_bib105","first-page":"61","article-title":"Epidemiology and clinical presentation of medullary thyroid carcinoma","volume":"204","author":"Raue","year":"2015","journal-title":"Recent Results in Cancer Res. Fortschritte der Krebsforschung Progres dans les recherches sur le cancer"},{"issue":"4","key":"10.1016\/j.mce.2024.112295_bib106","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrendo.2016.11","article-title":"A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma","volume":"12","author":"Romei","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib107","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-20-2278","article-title":"Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib","volume":"27","author":"Rosen","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib108","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","article-title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers","volume":"13","author":"Rosen","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mce.2024.112295_bib109","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.radonc.2019.03.033","article-title":"The role of external beam radiotherapy in the management of medullary carcinoma of the thyroid: a systematic review","volume":"136","author":"Rowell","year":"2019","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00000658-198301001-00007","article-title":"The surgical management of medullary thyroid carcinoma","volume":"197","author":"RUSSELL","year":"1983","journal-title":"Ann. Surg."},{"key":"10.1016\/j.mce.2024.112295_bib111","series-title":"Williams Textbook of Endocrinology","first-page":"449","article-title":"Chapter 14 - nontoxic diffuse goiter, nodular thyroid disorders, and thyroid malignancies","author":"Schlumberger","year":"2016"},{"issue":"11","key":"10.1016\/j.mce.2024.112295_bib112","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mce.2024.112295_bib113","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2021.09.012","article-title":"Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinoma","volume":"158","author":"Shankar","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib114","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41698-021-00188-x","article-title":"The L730V\/I RET roof mutations display different activities toward pralsetinib and selpercatinib","volume":"5","author":"Shen","year":"2021","journal-title":"npj Precis. Oncol."},{"issue":"24","key":"10.1016\/j.mce.2024.112295_bib115","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1002\/cncr.30252","article-title":"Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer","volume":"122","author":"Sherman","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib116","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41421-022-00479-y","article-title":"Integrated proteogenomic characterization of medullary thyroid carcinoma","volume":"8","author":"Shi","year":"2022","journal-title":"Cell Discov."},{"issue":"6","key":"10.1016\/j.mce.2024.112295_bib117","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/hed.27025","article-title":"American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment","volume":"44","author":"Shonka","year":"2022","journal-title":"Head Neck"},{"issue":"11","key":"10.1016\/j.mce.2024.112295_bib118","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJMoa043999","article-title":"Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A","volume":"353","author":"Skinner","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.mce.2024.112295_bib119","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.mce.2024.112295_bib120","article-title":"Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study","author":"Steward","year":"2018","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.mce.2024.112295_bib121","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.19.02551","article-title":"State-of-the-Art strategies for targeting RET-dependent cancers","volume":"38","author":"Subbiah","year":"2020","journal-title":"J. Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.mce.2024.112295_bib122","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic <em>RET<\/em>-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"10.1016\/j.mce.2024.112295_bib123","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.mce.2024.112295_bib124","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1089\/thy.2018.0351","article-title":"F-18-Dopa positron emission tomography\/computed tomography is more sensitive than whole-body magnetic resonance imaging for the localization of persistent\/recurrent disease of medullary thyroid cancer patients","volume":"29","author":"Terroir","year":"2019","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12020-021-02892-x","article-title":"Head-to-head comparison of FNA cytology vs. calcitonin measurement in FNA washout fluids (FNA-CT) to diagnose medullary thyroid carcinoma. A systematic review and meta-analysis","volume":"75","author":"Trimboli","year":"2022","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib126","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40463-018-0303-x","article-title":"Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer","volume":"47","author":"Turkdogan","year":"2018","journal-title":"J. Otolaryngol. Head Neck Surg."},{"issue":"7","key":"10.1016\/j.mce.2024.112295_bib127","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.oraloncology.2013.03.443","article-title":"Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging","volume":"49","author":"Tuttle","year":"2013","journal-title":"Oral Oncol."},{"issue":"12","key":"10.1016\/j.mce.2024.112295_bib128","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1089\/thy.2010.0178","volume":"20","author":"Tuttle","year":"2010","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/EJE-18-1008","article-title":"Clinico-pathologic and dynamic prognostic factors in sporadic and familial medullary thyroid carcinoma: an Israeli multi-center study","volume":"181","author":"Twito","year":"2019","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"10.1016\/j.mce.2024.112295_bib130","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/ERC-19-0259","article-title":"Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response","volume":"27","author":"Valerio","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"issue":"3","key":"10.1016\/j.mce.2024.112295_bib131","article-title":"Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules","volume":"3","author":"Verbeek","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib132","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cncr.24738","article-title":"Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer","volume":"116","author":"Walter","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.mce.2024.112295_bib133","article-title":"The diagnostic value of ultrasound in medullary thyroid carcinoma: a comparison with computed tomography","volume":"19","author":"Wang","year":"2020","journal-title":"Technol. Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.mce.2024.112295_bib134","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J. Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.mce.2024.112295_bib135","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1210\/jc.2013-1204","article-title":"Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update","volume":"98","author":"Wells","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.mce.2024.112295_bib136","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.mce.2024.112295_bib137","article-title":"Emergence and targeting of acquired and hereditary resistance to multikinase RET inhibition in patients with RET-altered cancer","volume":"3","author":"Wirth","year":"2019","journal-title":"JCO Precis Oncol."},{"issue":"9","key":"10.1016\/j.mce.2024.112295_bib138","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"15_Suppl. l","key":"10.1016\/j.mce.2024.112295_bib139","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1200\/JCO.2021.39.15_suppl.6074","article-title":"Efficacy of selpercatinib after prior systemic therapy in patients with RET mutant medullary thyroid cancer","volume":"39","author":"Wirth","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/onco.13977","article-title":"Patient-reported outcomes with selpercatinib treatment among patients with RET-mutant medullary thyroid cancer in the phase I\/II LIBRETTO-001 trial","volume":"27","author":"Wirth","year":"2022","journal-title":"Oncol."},{"issue":"28","key":"10.1016\/j.mce.2024.112295_bib141","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.2217\/fon-2022-0657","article-title":"LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naive RET-mutant medullary thyroid cancer","volume":"18","author":"Wirth","year":"2022","journal-title":"Future Oncol."},{"issue":"3","key":"10.1016\/j.mce.2024.112295_bib142","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hed.26550","article-title":"Limitations of preoperative cytology for medullary thyroid cancer: proposal for improved preoperative diagnosis for optimal initial medullary thyroid carcinoma specific surgery","volume":"43","author":"Workman","year":"2021","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.mce.2024.112295_bib143","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.21.01329","article-title":"International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma","volume":"40","author":"Xu","year":"2022","journal-title":"J. Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.mce.2024.112295_bib144","doi-asserted-by":"crossref","DOI":"10.1089\/thy.2019.0579","article-title":"Structural doubling time predicts overall survival in patients with medullary thyroid cancer in patients with rapidly progressive metastatic medullary thyroid cancer treated with molecular targeted therapies","author":"Yeh","year":"2020","journal-title":"Thyroid"}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720724001515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720724001515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T07:36:32Z","timestamp":1725694592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720724001515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":144,"alternative-id":["S0303720724001515"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2024.112295","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fundamentals and recent advances in the evaluation and management of medullary thyroid carcinoma","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2024.112295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112295"}}